Tenaya and Alnylam Enter Research Collaboration Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Source: NASDAQ.COM
- Collaboration Agreement: Tenaya Therapeutics has signed a research collaboration agreement with Alnylam Pharmaceuticals to discover potential human genetic targets for cardiovascular disease, marking a strategic partnership in gene therapy.
- Funding Support: Tenaya will receive up to $10 million in upfront payments along with reimbursement for related costs, ensuring sufficient funding for its research activities during the two-year validation period.
- Potential Earnings: Should all genetic targets lead to approved therapeutics, Tenaya could be eligible for up to $1.13 billion in development and commercial milestone payments, significantly enhancing its financial position and market competitiveness.
- Stock Price Reaction: In pre-market trading on Nasdaq, Tenaya's shares rose by 11.8% to $0.6499, reflecting positive market expectations and increased investor confidence regarding the collaboration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 282.850
Low
351.00
Averages
479.53
High
580.00
Current: 282.850
Low
351.00
Averages
479.53
High
580.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alnylam to Host 10th RNAi Roundtable Series
- RNAi Roundtable Series: Alnylam Pharmaceuticals announced its plan to host the 10th series of 'RNAi Roundtable' webinars in the coming months, featuring presentations from scientists and medical experts discussing recent advancements in the company's pipeline programs to address unmet clinical needs.
- Live Webcast Arrangement: Each event will be webcast live on the company's investor website, with replays available approximately three hours after each session, ensuring timely access to critical information for investors.
- 2030 Strategic Goals: Alnylam aims to increase its clinical programs from over 25 to more than 40 by 2030, demonstrating its commitment to sustainable innovation and market expansion in the RNAi therapeutics sector.
- Increased R&D Investment: The company is significantly ramping up its R&D investments to extend the application of RNAi technology, aiming to deliver multiple new transformative medicines for patients with serious diseases, thereby reinforcing its market leadership position.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Alnylam Partners with Inceptive in AI Collaboration
- Strategic Collaboration: Alnylam Pharmaceuticals has entered into a strategic AI partnership with Inceptive Nucleics valued at up to $2 billion, aiming to leverage Inceptive's generative AI models to accelerate the discovery of RNA interference therapeutics, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Market Rebound: Blackstone's shares rose 8% despite the firm limiting withdrawals from its Private Credit fund, indicating investor confidence as the stock is poised to end a three-day losing streak, reflecting a positive sentiment towards asset management firms.
- Stock Volatility: Broadcom's shares tumbled nearly 15% after reporting second-quarter revenue of $22.19 billion, falling short of the $22.27 billion expected by analysts, although CEO Hock Tan reiterated the company's fiscal year 2027 revenue guidance for AI chips to exceed $100 billion, raising concerns about future growth prospects.
- Healthcare Outlook: UnitedHealth's stock climbed 5% following an upgrade from Bank of America from neutral to buy, citing improving medical cost trends and supportive near-term data points that are expected to favorably impact second-quarter earnings, reflecting optimism in the health insurance sector.
See More
Mixed US Stock Market with Tech Stocks Under Pressure
- Tech Stock Decline: Broadcom (AVGO) shares plummeted over 15% after its AI revenue forecast fell short, marking it as the largest decliner in the Nasdaq 100, which reflects growing concerns about the tech sector and may dampen investor confidence.
- Weak Employment Data: Initial jobless claims in the US rose by 13,000 to 225,000, reaching a 3.75-month high, indicating a weakening labor market that could lead to downward revisions in growth expectations.
- Healthcare Stocks Strong: UnitedHealth Group (UNH) surged over 6%, leading gains in the S&P 500, after Bank of America upgraded its rating from neutral to buy with a price target of $450, showcasing resilience in the healthcare sector.
- International Market Volatility: European markets showed mixed results, with Eurozone April retail sales falling 0.4% month-over-month, worse than the expected 0.3%, indicating weak consumer spending that could pressure future economic growth.
See More
Alnylam Partners with Inceptive for $2 Billion AI-Driven Collaboration
- Strategic Partnership: Alnylam Pharmaceuticals has entered into a partnership with AI-driven biotechnology company Inceptive Nucleics in a deal valued at up to approximately $2 billion, aiming to combine expertise in RNA interference therapeutics with AI capabilities to accelerate the design and discovery of nucleic acid-based medicines.
- Technology Integration: By integrating Inceptive's generative AI models into its R&D platform, Alnylam plans to expedite RNAi drug discovery and advance its pipeline expansion goals outlined in the Alnylam 2030 strategy, thereby enhancing its competitive position in the market.
- Financial Terms: Under the agreement, Inceptive will receive a $30 million upfront payment and will be eligible for additional payments tied to the achievement of preclinical, regulatory, and commercial sales milestones, providing substantial financial support for Inceptive's technological advancements.
- Stock Market Reaction: Alnylam shares closed at $292.58 on Wednesday and rose more than 2% in after-hours trading, indicating a positive market response to the partnership, which may bolster investor confidence in the company's future growth potential.
See More
Alnylam to Host 10th RNAi Roundtable Series
- RNAi Roundtable Series: Alnylam Pharmaceuticals announced its plan to host the 10th series of 'RNAi Roundtable' webinars in the coming months, featuring presentations from scientists and medical experts discussing recent advancements in the company's pipeline programs to address unmet clinical needs.
- Live Webcast Arrangement: Each event will be webcast live on the company's investor website, with replays available approximately three hours after each session, ensuring timely access to critical information for investors.
- 2030 Strategic Goals: Alnylam aims to increase its clinical programs from over 25 to more than 40 by 2030, demonstrating its commitment to sustainable innovation and market expansion in the RNAi therapeutics sector.
- Increased R&D Investment: The company is significantly ramping up its R&D investments to extend the application of RNAi technology, aiming to deliver multiple new transformative medicines for patients with serious diseases, thereby reinforcing its market leadership position.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Alnylam Partners with Inceptive in AI Collaboration
- Strategic Collaboration: Alnylam Pharmaceuticals has entered into a strategic AI partnership with Inceptive Nucleics valued at up to $2 billion, aiming to leverage Inceptive's generative AI models to accelerate the discovery of RNA interference therapeutics, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Market Rebound: Blackstone's shares rose 8% despite the firm limiting withdrawals from its Private Credit fund, indicating investor confidence as the stock is poised to end a three-day losing streak, reflecting a positive sentiment towards asset management firms.
- Stock Volatility: Broadcom's shares tumbled nearly 15% after reporting second-quarter revenue of $22.19 billion, falling short of the $22.27 billion expected by analysts, although CEO Hock Tan reiterated the company's fiscal year 2027 revenue guidance for AI chips to exceed $100 billion, raising concerns about future growth prospects.
- Healthcare Outlook: UnitedHealth's stock climbed 5% following an upgrade from Bank of America from neutral to buy, citing improving medical cost trends and supportive near-term data points that are expected to favorably impact second-quarter earnings, reflecting optimism in the health insurance sector.
See More
Mixed US Stock Market with Tech Stocks Under Pressure
- Tech Stock Decline: Broadcom (AVGO) shares plummeted over 15% after its AI revenue forecast fell short, marking it as the largest decliner in the Nasdaq 100, which reflects growing concerns about the tech sector and may dampen investor confidence.
- Weak Employment Data: Initial jobless claims in the US rose by 13,000 to 225,000, reaching a 3.75-month high, indicating a weakening labor market that could lead to downward revisions in growth expectations.
- Healthcare Stocks Strong: UnitedHealth Group (UNH) surged over 6%, leading gains in the S&P 500, after Bank of America upgraded its rating from neutral to buy with a price target of $450, showcasing resilience in the healthcare sector.
- International Market Volatility: European markets showed mixed results, with Eurozone April retail sales falling 0.4% month-over-month, worse than the expected 0.3%, indicating weak consumer spending that could pressure future economic growth.
See More
Alnylam Partners with Inceptive for $2 Billion AI-Driven Collaboration
- Strategic Partnership: Alnylam Pharmaceuticals has entered into a partnership with AI-driven biotechnology company Inceptive Nucleics in a deal valued at up to approximately $2 billion, aiming to combine expertise in RNA interference therapeutics with AI capabilities to accelerate the design and discovery of nucleic acid-based medicines.
- Technology Integration: By integrating Inceptive's generative AI models into its R&D platform, Alnylam plans to expedite RNAi drug discovery and advance its pipeline expansion goals outlined in the Alnylam 2030 strategy, thereby enhancing its competitive position in the market.
- Financial Terms: Under the agreement, Inceptive will receive a $30 million upfront payment and will be eligible for additional payments tied to the achievement of preclinical, regulatory, and commercial sales milestones, providing substantial financial support for Inceptive's technological advancements.
- Stock Market Reaction: Alnylam shares closed at $292.58 on Wednesday and rose more than 2% in after-hours trading, indicating a positive market response to the partnership, which may bolster investor confidence in the company's future growth potential.
See More
